December 8, 2016

Drugmakers Want Tough Scrutiny of 340B Discount Program

Bloomberg posted an article titled, “Drugmakers Want Tough Scrutiny of 340B Discount Program.” The article reads in part as follows;

“A federal drug discount program for safety-net providers is experiencing rapid growth and deserves tough scrutiny, a group linked to drugmakers said Dec. 6.

The group, AIR 340B, said in a report the federal 340B drug pricing program is expected to reach $23 billion in total drug sales by 2021, up from the estimated program sales for 2016 of $16.1 billion. AIR 340B said the program’s growth has gone unchecked for too long and policymakers should re-examine it to ensure the program is serving its original intent to improve access to drugs for uninsured or vulnerable patients.

September 29, 2016

WELCH CONTINUES PUSH TO REIN IN SKYROCKETING PRESCRIPTION DRUG PRICES published an article titled, “Welch Continues Push to Rein in Skyrocketing Prescription Drug Prices.” The article reads in part as follows;

“Rep. Peter Welch (D-VT) today introduced bipartisan legislation with Rep. Morgan Griffith (R-VA) that would address a loophole in the Medicare 340B Drug Pricing Program that is contributing to the rising cost of health care for consumers and threatening access to lifesaving medications. The introduction of this legislation is the latest in Welch’s efforts to fix the broken prescription drug market that has led to unrestrained price increases for consumers and providers.

August 19, 2016

Demonstrating That 340(b) Loses Are Recouped By Increased Prices To The Public

The shortcomings in the 340(b) program have been studied for years.  One reason for the lack of action is that the implications of these shortcomings have not been presented in a manner that demonstrates they affect the consumer. In essence it appears that certain commercial sectors, pharmacies and hospitals, are benefiting at the cost of the pharmaceutical industry.

One purpose of this Interactive Public Docket(IPD) is to subject this public policy issue to an informed analysis with an interactive capability for all interested stakeholders to express their views and submit relevant data. To this end CRE controls all original posts on this page, the home page, but interested stakeholders may post directly on the two forums to the right of this page. Our readers can, however, post comments on CRE articles on the home page but they cannot post a new article.